

# Prescription Drug Technical Advisory Group

October 12, 2022

Christina McLaughlin, Health Policy Advisor, GMCB

# Background

- Per Act 48, the Green Mountain Care Board has the authority to establish advisory groups as needed to carry out its duties (18 V.S.A. § 9374).
- In May of 2020, the Board discussed forming a Prescription Drug Technical Advisory Group at a public meeting after the House Health Care Committee proposed the idea during the 2020 legislative session.
- While the Board does not have any authority over the cost of prescription drugs, it is consistently a major cost driver in health insurance rate and hospital budgets rate increases.

# Advisory Group Overview

- The Board convened the Prescription Drug Advisory Group in December 2020.
- Group Membership
  - The group consists of 12 active members, including representatives from the VT Attorney General's Office, VT Association of Hospitals and Health Systems, UVM Health Network, BCBSVT, MVP Health Care, pharmacists, the Health Care Advocate's Office, other state agencies, plus GMCB staff and a designated Board member.
- Meeting Materials
  - All agendas, materials, and minutes are posted to the [Prescription Drug Advisory Group page](#) on the GMCB website.

# Advisory Group Timeline

**December 2020**

The Prescription Drug Advisory Group convened its first public meeting.

**Summer 2022**


The affordability subgroup and PBM regulation subgroup adjourned.

**Spring 2021 –  
Spring 2022**

The affordability subgroup and PBM regulation subgroup convened, occasionally sharing recommendations/updates.

**Fall 2022**

Convened public meeting to determine future work. Group members agreed to continue the Prescription Drug Advisory Group.



# Related Legislation

- Legislation passed in 2022
  - [Act 131 \(H.353\) – An act relating to pharmacy benefit management](#)
- Legislation not passed in 2022
  - [S.243 - An act relating to implementation of an unused prescription drug repository program](#)
    - The Vermont Department of Health testified they did not need a bill to pursue the feasibility analysis and assured the legislature its intent to perform the research with or without legislation.
  - [S.193 – An act relating to strategies for reducing prescription drug costs for Vermonters](#)

# Questions for Discussion

1. Would the Board like to continue the Prescription Drug Advisory Group?
2. If yes, which Board member will staff the Advisory Group moving forward?